Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis

Liver Transplantation

Volumn 13, Issue 1, 2007, Pages 21-29

  Berenguer, Marina ^a   Royuela, Ana ^b   Zamora, Javier ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; METHYLPREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; META ANALYSIS; MICROEMULSION; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIREMIA;

BIOPSY; CALCINEURIN; CLINICAL TRIALS; CYCLOSPORINE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; RECURRENCE; RESEARCH DESIGN; RISK; TACROLIMUS; TREATMENT OUTCOME;

EID: 33846238124     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21035     Document Type: Review

References (60)

1. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and Liver transplantation. J Hepatol 2001;35:666-678.
2. Wiesner RH, Sorrell M, Villamil F. Report of the First International Liver Transplant Society Consensus Conference on Liver Transplantation and Hepatitis C. Liver Transpl 2003;9:S1-S9.
3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003,9:S28-S34.
4. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
5. Forman LM, Dewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896.
6. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226-231.
7. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation. J Hepatol 2005;42:448-456.
8. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003;9:S63-S66.
9. Watashi K, Hijikata M, Hosaka M, Yamagi M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38: 1282-1288.
10. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031-1041.
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
12. Deeks JJ, Altman DG, Bradburn MJ: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey SG, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. BMJ Books;2001:285-312.
13. RevMan Analyses [Computer program]. Version 1.0 for Windows. In: Review Manager (RevMan) 4.2. Oxford, England: The Cochrane Collaboration, 2003.
14. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C. Impact of tacrolimus vs. cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis C: a prospective randomized trial. Liver Transpl 2004;10:1258-1262.
15. Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998;65:1044-1046.
16. Wiesner RH, for the United States FK506 Study Group. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66:493-499.
17. Mueller AR, Platz KP, Bechstein WO, Blumhardt G, Christe W, Hopf U, et al. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine or FK 506?. Clin Transplant 1995;9:176-184.
18. Berenguer M, Aguilera. V, Martín Prieto, Juan FS, Rayon JM, Benlloch S, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006;12:762-767.
19. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
20. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005;11:386-395.
21. Brillanti S, Vivarelli M, De RN, Aden AA, Camaggi V, D'Errico A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002:8:884-888.
22. Belli LS, Alberti AB, Vangeli M, Airoldi A, Pinzello G. Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl 2003;9:201-202.
23. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
24. Fung J, Eghtesad B, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl 2004;10:S39-S53.
25. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32(Pt 1):852-858.
26. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-369.
27. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38:34-41.
28. The U.S. Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-1115.
29. The European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994;344:423-428.
30. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with CO monitoring in the novo liver transplantation. Transplantation 2004;77:1632-1638.
31. Rosen HR. Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl 2003;9:S35-S43.
32. Mueller AR, Platz KP, Bechstein WO, Blumhardt G, Lobeck H, Hop U, Neuhaus P. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. Transplant Proc 1994;26:3637-3639.
33. McCaughan GW. Immunosuppression for HCV following liver transplantation: enough is just enough. Transplantation 2004;78:1413-1414.
34. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
35. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
36. Johnson MW, Washburn WK, Freeman RB, FitzMaurice SE, Dienstag J, Basgoz N, et al. Hepatitis C viral infection in liver transplantation. Arch Surg 1996;131:284-291.
37. Boker KH, Dalley G, Bahr MJ, Maschek H, Tillmann HL, Trautwein C, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997;25: 203-210.
38. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
39. Platz KP, Mueller AR, Willimski C, Mansoorian B, Berg T, Neuhaus R, et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. Transplant Proc 1998;30:1468-1469.
40. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
41. Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-831.
42. Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut 1999;45:427-434.
43. Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000;6:553-561.
44. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
45. Pelletier SJ, Lezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000;6:44-53.
46. Sreekumar R, Gonzalez-Koch A. Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-1130.
47. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-393.
48. Hunt J, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, Khettry U. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 2001;7:1056-1063.
49. Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001:72:412-418.
50. Bilbao I, Pou L, Allende E, Lazaro JL, Charco R, Hidalgo E, Margarit C. Comparison between tacrolimus and Neoral cyclosporine administered by oral route in liver transplantation. Transplant Proc 2001;33:2124-2126.
51. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F. Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
52. Paik SW, Tan HP, Klein AS, Boitnott JK, Thuluvath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci 2002;47:450-455.
53. Sanchez-Fueyo A, Restrepo JC. Quinto L, Bruguera M, Grande L, Sanchez-Tapias JM, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002;73:56-63.
54. Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayon M, San Juan F, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003;9:1152-1158.
55. Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003;9:796-804.
56. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R. et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
57. Rimola. A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X, et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004;78:686-691.
58. Bahr MJ, Beckermann JG, Rifai K, Gehrmann L, Rosenau J, Klempnauer J, et al. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. Transplant Proc 2005;37:1703-1704.
59. Lucey MR, Abdelmalek MF, Gagliardi R, Granger D, Holt C, Kam I, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005;5:1111-1119.
60. Neuhaus P, Bechstein WO, Blumhardt G, Wiens M, Lemmens P, Langrehr JM, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993;55:1320-1327.